Advertisement

Document › Details
Medivir AB. (9/11/17). "Press Release: Medivir Announces Janssen to Discontinue Development of JNJ-4178 for Hepatitis C". Stockholm.
![]() |
Organisation | Medivir AB (Nasdaq Stockholm: MVIR) |
Today | Medivir (Group) | |
Group | Medivir (Group) | |
Organisation 2 | Janssen Research & Development LLC | |
Group | Johnson & Johnson (JnJ) (Group) | |
![]() |
Product | JNJ-4178 (JnJ) |
Product 2 | Olysio™ | |
![]() |
Person | Lind, Christine (Medivir 201704– CEO before EVP Strategic BusDev before LifeCellCorp + Merrill Lynch/BoAML in NY) |
Medivir AB (Nasdaq Stockholm: MVIR) today announces that Janssen Research & Development has decided to discontinue the development of the investigational hepatitis C treatment, JNJ-4178, the triple combination of simeprevir, odalasvir and AL-335. Discontinuation of development of JNJ-4178 does not affect the ongoing partnership with Janssen on Olysio® (simeprevir), or the existing licensing agreement with Janssen in which simeprevir is included. Medivir continues to be entitled to royalties on sales of single agent simeprevir globally.
The decision to terminate the development of JNJ-4178 was made in light of increasing competition due to the availability of a number of effective therapies for hepatitis C. The ongoing phase II studies with JNJ-4178 will continue as planned, but there will be no additional development thereafter.
”Although Janssen’s decision not to progress this promising treatment further is unfortunate, Medivir’s focus does not change” says Christine Lind, CEO at Medivir. She continues, “We continue to develop our proprietary pipeline in oncology and look forward to completing the ongoing Phase IIa studies in osteoarthritis.”
For further information, please contact:
Christine Lind, CEO, mobile: +46 (0)72-710 2205
Medivir AB is obliged to make this information public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 CET on 11 September 2017.
About Medivir
Medivir is a research-based pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical needs. Medivir is listed on the Nasdaq Stockholm Mid Cap List.
Record changed: 2017-09-25 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for Medivir (Group)
- [1] Pharmanest AB. (5/18/18). "Press Release: Helena Jansson Appointed as New CEO of Pharmanest"....
- [2] Medivir AB. (12/10/17). "Press Release: Medivir Announces Janssen Decision to Terminate Its Simeprevir License effective June 2018". Stockholm....
- [3] Medivir AB. (11/10/17). "Press Release: Medivir Appoints Christina Herder as Executive Vice President Strategic Business Development". Stockholm....
- [4] Medivir AB. (11/3/17). "Press Release: Medivir Appoints Erik Björk as Chief Financial Officer". Stockholm....
- [5] Medivir AB. (8/18/17). "Press Release: Medivir Licenses Exclusive Rights to MIV-802 for Greater China to Ascletis". Stockholm & Hangzhou....
- [6] Medivir AB. (8/16/17). "Press Release: FDA Accepts Medivir´s IND Application for MIV-711, Enabling Clinical Development in the US". Stockholm....
- [7] Medivir AB. (3/16/17). "Press Release: Medivir Completes Transition of Commercial Products to Fully Focus on Research and Development". Stockholm....
- [8] Medivir AB. (2/17/17). "Press Release: Financial Statement, January – December 2016"....
- [9] Medivir AB. (2/17/17). "Press Release: Executive Management Team Members Increase their Holdings in Medivir". Stockholm....
- [10] Medivir AB. (2/9/17). "Press Release: Christine Lind New CEO of Medivir AB Effective 1 April 2017". Stockholm....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top